TAM
KYNB

Tiverton Asset Management’s Kyntra Bio KYNB Stock Holding History

Tiverton Asset Management’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-185
Closed -$252K – 697
2019
Q1 		$252K Sell
185
-22
-11% -$29.8K 0.01% 503
2018
Q4 		$239K Buy
+207
New +$233K 0.01% 291

Other funds holding KYNB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Tiverton Asset Management's KYNB Position: Q2 2019 in Review

Tiverton Asset Management sold out of Kyntra Bio (KYNB) in Q2 2019, closing a stake of 185 shares — an estimated $252K sold.

Tiverton Asset Management first reported a position in KYNB in Q4 2018 and held it in 2 quarters. The position peaked at $252K in Q1 2019. 190 funds tracked by Wall St. Rank hold KYNB as of Q2 2019.

  • Tiverton Asset Management reported no remaining Kyntra Bio position as of Q2 2019 after selling out during the quarter.
  • Tiverton Asset Management sold 185 Kyntra Bio shares in Q2 2019, an estimated $252K.
  • Tiverton Asset Management first reported a position in Kyntra Bio in Q4 2018 and held it in 2 quarters.
  • Tiverton Asset Management's Kyntra Bio position peaked at $252K in Q1 2019.
  • 190 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2019.

Based on Tiverton Asset Management's 13F filing for Q2 2019, filed 12 Aug 2019.